Syros (SYRS) Stock Rises More Than 35% in 3 Months: Here's Why
ANI's Generic L-Glutamine Oral Powder Hits Market, Targets $20.1M Annual Sales
ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (
Express News | ANI Pharmaceuticals Announces the FDA Approval and Launch of L-Glutamine Oral Powder
ANI Pharmaceuticals (NASDAQ:ANIP) Shareholder Returns Have Been Decent, Earning 95% in 3 Years
By buying an index fund, you can roughly match the market return with ease. But if you buy good businesses at attractive prices, your portfolio returns could exceed the average market return. Just
ANI Pharmaceuticals(ANIP.US) Officer Sells US$1.27 Million in Common Stock
$ANI Pharmaceuticals(ANIP.US)$ Officer Gassert Chad sold 20,000 shares of common stock on Jul 1, 2024 at an average price of $63.44 for a total value of $1.27 million.Source: Announcement What is stat
Express News | Corrected-ANI Pharmaceuticals - U.S. Annual Sales for Naproxen Tablets About $36.7 Mln, Based on April Mat IQVIA Data (Adds Dropped Words 'based on April Mat IQVIA Data')
Express News | ANI Pharmaceuticals Announces FDA Approval And Launch Of Its Naproxen Delayed-Release Tablets, USP
Express News | ANI Pharmaceuticals Inc - U.S. Annual Sales for Naproxen Tablets Approximately $36.7 Million
Express News | ANI Pharmaceuticals Announces the FDA Approval and Launch of Naproxen Delayed-Release Tablets, Usp
NVIDIA To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Citigroup r
ANI Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
ANI Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
ANI Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/26/2024 46.44% HC Wainwright & Co. $87 → $94 Maintains Buy 05/13/2024 35.54% HC Wainwright & Co. $83 →
H.C. Wainwright Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating, Raises Target Price to $94
H.C. Wainwright analyst Oren Livnat maintains $ANI Pharmaceuticals(ANIP.US)$ with a buy rating, and adjusts the target price from $87 to $94.According to TipRanks data, the analyst has a success rate
Express News | ANI Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $94 From $87
Alimera (ALIM) Rises on Merger Deal With ANI Pharmaceuticals
Truist Financial Maintains ANI Pharmaceuticals(ANIP.US) With Buy Rating
Truist Financial analyst Les Sulewski maintains $ANI Pharmaceuticals(ANIP.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 65.9% and a total average return of 14.8%
Express News | ANI Pharmaceuticals’ CEO Nikhil Lalwani Named Ey Entrepreneur of the Year® 2024 New Jersey Award Winner
Nasdaq Records Worst Session Since April With Nvidia Plunging 7%: Dow Jones Sees Modest Gains Amid Mixed Market Close
The CNN Money Fear and Greed index showed some improvement in the overall market sentiment, while the index remained in the "Fear" zone on Monday.U.S. stocks closed mixed on Monday, with the Dow Jones
ANI Pharmaceuticals(ANIP.US) Officer Sells US$1.18 Million in Common Stock
$ANI Pharmaceuticals(ANIP.US)$ Officer Shanmugam Muthusamy sold 20,000 shares of common stock on Jun 21, 2024 at an average price of $58.9 for a total value of $1.18 million.Source: Announcement What
Generics Player ANI Pharmaceuticals Strengthens Rare Disease Segment With $380M Alimera Sciences Deal
On Monday, ANI Pharmaceuticals Inc (NASDAQ:ANIP) agreed to acquire Alimera Sciences Inc (NASDAQ:ALIM) for $5.50 per share in cash and one non-tradable contingent value right (CVR) of up to $0.50 per s